Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
18 Março 2024 - 9:00AM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that it has expanded its senior management team with the
addition of Sandra Milligan, M.D., J.D. as President effective
April 1, 2024. Dr. Milligan will report to Nicole Sandford, who
will remain CEO. The Company has also promoted Dr. Todd Pappas,
Vice President of Research & Development, to lead the Company’s
product development team reporting directly to Dr. Milligan,
following the departure of Dr. Jody Berry.
Dr. Milligan is an accomplished and proven leader with 25+ years
of experience in the healthcare sector, with corporate experience
that includes executive roles of increasing responsibility at
innovative biopharmaceutical companies such as Amgen, Genentech,
Merck, and Organon. She has demonstrated success in supporting
pipeline and product development in both oncology and non-oncology
disease areas, with recent emphasis in women’s health. Dr. Milligan
is a known and respected leader in women’s health who drives
cross-functional strategies to achieve corporate success.
As President, Dr. Milligan will be a key member of the executive
leadership team with direct responsibility for the Research and
Development, Operations, Information Technology, and Human
Resources functions. Her immediate focus will be on accelerating
the launch of the Company’s in-development products and the
identification of potential innovation and commercialization
partnerships.
“I am thrilled to welcome Sandy to our senior leadership team.
She is a dynamic executive with the depth and breadth of experience
and pharmaceutical and women's health industry relationships we
need to take advantage of the opportunities before us,” said Nicole
Sandford, Chief Executive Officer of Aspira. “With Sandy focused on
the successful achievement of our innovation and operational goals,
I will direct more of my attention on the acceleration of our
growth initiatives, the expansion of our shareholder base, and the
achievement of our long-term vision as a world-class AI-driven
diagnostic company. She joins an already strong executive
leadership team of experienced professionals. I also congratulate
Todd who takes his rightful place at the helm of our R&D effort
having been with Aspira for nearly a decade. We all thank Dr. Berry
for his contributions to our progress and wish him well in his
future endeavors.”
Dr. Milligan said, “I am excited to join a team dedicated to
enhancing outcomes for the millions of women suffering from
gynecologic disease. Advocating for improvements in women’s health
has been important to me throughout my career, and I believe
Aspira’s pipeline of advanced diagnostic tools for ovarian cancer
and endometriosis address a real unmet need for healthcare
providers seeking to elevate the standard of care for women facing
these devastating diseases. I look forward to working with everyone
- from the laboratory bench to the field sales team - to realize
Aspira’s potential as a world-class diagnostic company.”
Dr. Milligan joins Aspira from her role as Executive Vice
President, Research and Development at Organon where she founded
the R&D organization and advanced near-and long-term strategies
for pipeline growth and value creation. Prior to Organon, she
served as Senior Vice President, Global Regulatory Affairs and
Clinical Safety at Merck where she developed and implemented
proactive, worldwide strategies across a broad spectrum of
therapeutics to enable rapid registration and robust life-cycle
enhancement. Prior to Merck, Dr. Milligan served in advancing
leadership roles in Research and Development at both Genentech and
Amgen. Dr. Milligan earned a Doctor of Medicine from the George
Washington University School of Medicine as well as a Juris Doctor
from Georgetown University Law Center. After serving as a General
Medical Officer in the US Army Medical Corps, she began her
corporate career as an attorney in healthcare and corporate law
prior to joining the pharmaceutical industry. She currently serves
on the board of Gossamer Bio, a clinical-stage biopharmaceutical
company focused on discovering, developing, and commercializing
therapeutics in respiratory disease. She formerly served as board
chair of DIA, a global organization that mobilizes life sciences
professionals across multiple disciplines involved in drug
development to take a collaborative approach to solve common
challenges.
Dr. Todd Pappas, Vice President of Research and Development, has
assumed responsibilities for product development, replacing Dr.
Jody Berry, who stepped down earlier this month. Dr. Pappas first
joined Aspira in 2013 and has experience in R&D, commercial,
and clinical operations at Aspira, Delphi, Inc., Reliant Immune
Diagnostics, and Luminex Corporation. His work has been central to
the successful development of the OvaSuite test portfolio. Dr.
Pappas will continue to be responsible for all aspects of Aspira’s
scientific and product development activities and its relationships
with academic partners, including Dana Farber Cancer Institute. Dr.
Pappas received his Ph.D. in Neuroscience from The University of
Texas Medical Branch at Galveston, and an MS in Biology from
California State University, Long Beach.
About Aspira Women’s Health Inc. Aspira
Women’s Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is a reflex
process of two FDA-cleared tests, Ova1® and Overa®, to assess the
risk of ovarian malignancy in women planned for
surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking
Statements This press release may contain
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including those
relating to the timing and completion of any products in the
pipeline development and other statement that are predictive in
nature. Actual results could differ materially from those discussed
due to known and unknown risks, uncertainties, and other factors.
These forward-looking statements generally can be identified by the
use of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors are not
guarantees of future performance and undue reliance should not be
placed on them. Such forward-looking statements necessarily involve
known and unknown risks and uncertainties, which may cause actual
performance and financial results in future periods to differ
materially from any projections of future performance or result
expressed or implied by such forward looking statements. These and
additional risks and uncertainties are described more fully in the
Company’s filings with the SEC, including those factors identified
as “risk factors” in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise, except as required by law.
Investor Relations Contact: Torsten
Hombeck, Ph.D. Chief Financial Officer Aspira Women’s
Health Investors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024